Editors Note: PDE11, the newest member of the PDE family of phosphodiesterases, has become the center of controversy. Four splice variants were recently identified, PDE11A1-4. Historical data have suggested that PDE11A3 is found in the testis while PDE11A4 is found in the prostate. The controversial issue is the inhibition of PDE11 by tadalafil. In the light of tadalafil's commercial success, its inhibition of PDE11A has been the subject of heated debate. A variety of published reports addressed this issue, suggesting that the target organ of tadalafil's inhibition, the testis, is not adversely affected. Daily tadalafil given to healthy volunteers did not alter semen analysis parameters or blood hormonal parameters, seemingly mitigating the clinical effect of the PDE11 inhibition. However, two recent papers published in this journal have added fuel to this proverbial fire. In this perspective, Sharron Francis, a noted PDE expert, and a co-author of one of the recent papers mentioned above, sheds further light on this contested topic.
This Perspective discusses two recent reports in IJIR; both focused on phosphodiesterase-11 (PDE11), which hydrolyzes the cyclic phosphate ring in cAMP and cGMP, thereby inactivating these molecules as second messengers. The reports used different approaches to study the physiological role of PDE11 and implications for potential tadalafil (marketed by Lilly ICOS as Cialis s ) inhibition of PDE11 in men using this medication for treatment of erectile dysfunction (ED). Loughney, Taylor and Florio rigorously assessed distribution of PDE11 in human tissues, an important contribution since there are conflicting reports on this topic in the literature. Wayman et al used PDE11 knockout mice to examine a role of this enzyme in sperm physiology and as a basis for considering potential implications of inhibition of PDE11 activity by tadalafil. In combination with results from earlier studies, these reports have generated considerable discussion in the scientific community and will hopefully encourage more studies of PDE11 function and further address the safety profile of tadalafil.
There is strong interest in PDE11 since its physiological role is unknown, and its structure is most closely related to phosphodiesterase-5 (PDE5), the target of commercially marketed inhibitors, sildenafil (Viagra 
. Despite having 50% identity in aminoacid sequence with the catalytic domain of PDE5, PDE11 is not significantly inhibited by sildenafil or vardenafil, but tadalafil has modest inhibitory potency. Tadalafil reportedly inhibits catalytic activity of one PDE11 isoform (PDE11A1) at concentrations within the therapeutic range (Cialis s package insert, Lilly ICOS, 2003) . Nevertheless, the likelihood that tadalafil significantly inhibits PDE11 activity has been questioned based on the B40-fold weaker potency for PDE11A4 than for PDE5. However, tadalafil market share for treatment of ED is growing rapidly, and some individuals are opting for regularly-timed administration of the medication rather than a more sporadic 'on-demand' usage. The paucity of information regarding PDE11 function combined with the potential for tadalafil inhibition of its activity is a source of some concern in the medical and scientific communities.
The Loughney studies were very straightforward, that is, if PDE11 is important in a tissue, one would expect to find the protein in some abundance therein. In human tissues, PDE11A4 was the only isoform identified and was detected only in the liver, pituitary, glandular epithelium of prostate, and neuronal cells in parasympathethic ganglia in the heart. PDE11 was not found in the testis, penis, or skeletal muscle. The merit of these results depends entirely on the specificity and the sensitivity of the methodology used. One can never be absolutely positive that experiments are flawless, but by all reasonable measures, the approaches used by Loughney and colleagues were rigorous, highly sensitive, and well controlled. First, they used a collection of human tissues, and the testicular tissue samples were derived from three individuals and a pool of tissue from 18 men (age range 19-64 y). Second, PDE11 protein standards for all four isoforms were employed to verify appropriate molecular weights for proteins detected by the antisera. Third, two potent antibodies specific to different regions of the catalytic domain shared by all PDE11 isoforms were used; this, in combination with comparison of the migration of the bands with PDE11 protein standards, lends veracity to identification of the protein bands. Fourth, the work focused on PDE11 proteins and not on mRNA transcripts; despite a common misconception that mRNA levels mirror those of the protein product, myriad examples demonstrate this to be untrue. In these studies, Loughney and co-workers were unable to detect PDE11 in the human testis. This does not exclude the possibility that PDE11 could be present in either very low levels or in minor subcellular compartments, but it weakens the case for a major role of PDE11 in the human testis. Results from this study should also focus more attention on potential effects of PDE11 inhibition in pituitary, liver, prostate glandular epithelium, and neurons in the heart.
Wayman et al took a very different approach by creating a PDE11 knockout mouse in an effort to uncover a physiological role for PDE11. Their report documented PDE11 expression in the testis and developing spermatogonia of wild-type mice. Modest changes were noted in ejaculated sperm from PDE11-null mice including reduction in forward progression of sperm (30%) with no change in overall motility, sperm concentration (20%), and live sperm (20%). Pre-ejaculated sperm of PDE11-null mice were somewhat more likely (29%) to have undergone capacitance compared to wild-type mice (19%). Despite this, the fertility rate of PDE11-null mice was comparable to that of wild-type mice, and there were no apparent differences in viability, histological features, or anatomical abnormalities. These results suggest that PDE11 may have some function in murine sperm, but its absence does not translate into a functionally significant phenotype. This could be due either to no role for PDE11 in the testis or compensatory upregulation of other PDEs that can replace the function normally provided by PDE11.
Interpretation of results derived from studies of knockout animals has significant limitations and caution is indicated. A major consideration is the well-established species variation in tissue expression of proteins; in many instances, nature has used different complements of closely related proteins to achieve the same end effect in a given tissue. The Loughney studies could not detect PDE11 in the human testis. While the presence of PDE11 in the human testis cannot be entirely excluded, these results argue against a major role for PDE11. This is in contrast to the apparent presence of PDE11 in murine testis and sperm.
While PDE11 may be abundantly expressed and have a modest role in murine sperm physiology, implications for human sperm function are questionable. Other workers have questioned the relevance of the rat or dog as models for studying the effect on spermatogenesis. In addition, the importance of a role for PDE11 in murine sperm physiology is questionable since its absence did not impair fertility or viability of offspring. PDE11-null mice provide a model of an animal with chronically and quantitatively inhibited PDE11. In these mice, PDE11 is absent throughout development and adulthood; currently, only adult male patients are exposed to tadalafil and the potential for inhibition of PDE11 is typically limited. Even though tadalafil may reach plasma concentrations capable of partially blocking PDE11 activity, this is most likely a transient phenomenon, and based on dosing regimens followed by most individuals, few men are exposed to such levels on a daily basis. Therefore, a persistent and high degree of PDE11 inhibition seems unlikely.
Given the concern for potential tadalafil inhibition of PDE11 within therapeutic range and the dearth of information regarding the physiological role of PDE11 in humans, it seems reasonable to suggest more comprehensive clinical studies particularly relating to the effect of tadalafil on testicular function, germ cell viability, and characteristics of prostatic fluid. The most comprehensive study included only men above 45 y of age who suffer from mild ED; this study found no adverse effects of daily intake of tadalafil, but some criticisms have been voiced. The complex biology of cyclic nucleotide signaling and modulation of these pathways by medications such as tadalafil provide impetus for continued efforts to develop a thorough understanding of the effects of these compounds and validation of their safety profiles.
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